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Abstract: The combination of calcipotriol with methotrexate can strengthen the topical therapy 
for psoriasis. The aim of the present study was to evaluate the potential of nanostructured 
lipid carriers (NLCs) loaded with lipophilic calcipotriol and hydrophilic methotrexate as 
topical therapy. NLCs composed of Precirol ATO 5 with various amounts of squalene as the 
liquid lipid were prepared. The particle size, surface charge, molecular environment, drug 
  permeation, and skin irritation of the carriers were assessed. Hyperproliferative skin was also 
used as a permeation barrier in this study. It was found that variations in the Precirol®/squalene 
ratio had profound effects on the physicochemical characteristics of the NLCs. The range of 
particle size of the NLC preparations was 270 to 320 nm, with vehicles containing a higher 
Precirol amount exhibiting a larger diameter. NLCs with a higher Precirol/squalene ratio also 
showed greater polarity in their molecular environment. Calcipotriol-loaded NLC systems 
provided drug fluxes of 0.62 to 1.08 µg/cm2/h, which were slightly higher or comparable to 
the 30% ethanol vehicle (control, 0.72 µg/cm2/h). The methotrexate amount permeating the 
skin was 2.4 to 4.4-times greater using NLCs compared to that with the control. Dual drug-
loaded NLCs exhibited reduced skin permeation of calcipotriol but not methotrexate. The 
in vivo topical delivery examined by confocal laser scanning microscopy (CLSM) showed a 
good correlation with the in vitro results. These two drugs with extremely different polarities 
can successfully be combined in NLCs. Results suggest that NLCs may have the potential to 
serve as delivery carriers for antipsoriatic drugs because of enhanced drug permeation and 
limited skin irritation.
Keywords: psoriasis, calcipotriol, methotrexate, nanostructured lipid carriers, topical 
  delivery
Introduction
Psoriasis is one of the most common human skin diseases. It is characterized by 
excessive growth and aberrant differentiation of keratinocytes.1,2 Topical therapy is 
the mainstay of treatment for mild to moderate psoriasis and often the initial treatment 
for severe psoriasis. About 80% of patients with psoriasis are treated topically.3 
No single topical medication is perfect by itself in the management of psoriasis; 
however, combined regimens with more than one medication are often beneficial.4 
Calcipotriol (Figure 1) is a synthetically prepared vitamin D3 analogue used for the 
treatment of psoriasis.5 Calcipotriol leads to cutaneous irritant reactions in ∼20% of 
patients.6 Calcipotriol combined with other therapies may allow the use of a reduced 
dose, thus minimizing the skin irritation. It can be used in combination with topical 
corticosteroids, ultraviolet (UV)B, psoralen-UVA, acitretin, cyclosporine, tazarotene, 
and methotrexate.7–9International Journal of Nanomedicine 2010:5 118
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The greatest limitation to the combined therapy is the 
inconvenience of administration. A drug vehicle should first 
be applied to the skin, followed by another drug vehicle after 
a determined duration. The two drugs incorporated in one 
formulation would likely result in better patient compliance. 
However, it is not easy to incorporate two drugs with extremely 
different polarities into a single vehicle, eg, calcipotriol (parti-
tion coefficient log P = 4.6) and methotrexate (Figure 1, log 
P = −2.2). A carrier with both lipid and aqueous phases such 
as emulsions and creams may overcome this problem. Solid 
lipid nanoparticles (SLNs) are the new generation of oil-in-
water nanoparticulate systems and are attracting attention 
as novel colloidal drug carriers for topical use. SLNs have 
many advantages, such as controlled release and enhanced 
bioavailability.10,11 Nanostructured lipid carriers (NLCs) 
are considered to be the smartest, latest generation of SLNs 
possessing improved properties of drug loading, modulation 
of the release profile, and stable drug incorporation during 
storage.12 NLCs are produced by mixing solid lipids with 
spatially incompatible lipids leading to a lipid matrix with a 
special structure.
At the molecular and cellular levels, calcipotriol and 
methotrexate have different modes of action. The combination 
of these two drugs can successfully be used in practice.13 
Although SLNs and NLCs are used as the carriers for single 
drug in several studies, the study about dual drugs in one 
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formulation for these nanocarriers is very few. The aim of this 
study was to try to incorporate calcipotriol and methotrexate 
in NLC systems for topical delivery. The present work 
  evaluated the possibility of producing NLCs containing 
two drugs, and their delivery to the skin was examined. The 
  physicochemical properties of the obtained NLCs, such as the 
size, zeta potential, and polarity, were investigated. Moreover, 
  hyperproliferative skin was used as a skin barrier for drug 
permeation in order to mimic a clinical situation.
Materials and methods
Materials
Calcipotriol was purchased from 21CEC (East Sussex, UK). 
Methotrexate, squalene, Pluronic® F68 (PF68), Nile red, 
sulforhodamine B (SRB), and fluorescein isothiocyanate 
(FITC) were supplied by Sigma Chemicals (St. Louis, 
MO, USA). Precirol® ATO 5, a mixture of 8% to 22% 
monoacyl, 40% to 60% diacyl, and 25% to 35% triacyl 
glyceryl palmitate and 40% to 60% stearate, was obtained 
from Gattefossé (Gennevilliers, France). Myverol™ 18-04K 
(palmitinic acid monoglycerides) was from Quest (Naarden, 
The Netherlands).
Preparation of NLCs
The Precirol and squalene mixture (10%, w/v of the final 
  product), as well as Myverol (0.2%) were dissolved in an 
appropriate volume of chloroform: methanol (2:1). The 
organic solvent was evaporated in a rotary evaporator at 
50°C to obtain a thin film, and solvent traces were removed 
by maintaining the film under a vacuum for 6 hours. The film 
was hydrated with PF68 (2.8%) and double-distilled water 
using a high-shear homogenizer (Pro250, ProScientific, 
  Monroe, CT, USA) for 10 min at 85°C. The mixture was 
further treated using a probe-type sonicator (VCX600, Sonics 
and Materials, Newtown, CT, USA) for 30 min at 85°C. The 
total volume of the final product was 10 mL. Calcipotriol 
(0.06%) and methotrexate (0.08%) were respectively 
  positioned in the lipid and aqueous phases.
Determination of the particle size  
and zeta potential
The mean particle size (z-average) and zeta potential of the 
NLCs were measured by photon correlation spectroscopy 
(Nanosizer ZS90, Malvern, Worcestershire, UK) using a He-
Ne laser at a wavelength of 633 nm. Photon correlations of 
spectroscopic measurements were carried out at a scattering 
angle of 90°. The NLCs were diluted 1:100 with water before 
the measurement.
Molecular environment of NLCs
The lipophilic fluorescent marker, Nile red, was used as the 
model solute, and the molecular environment (polarity) was 
determined by fluorometric spectrophotometry based on the 
solvatochromism of Nile red. The NLCs with 1 ppm Nile red 
were prepared as described above. Emission fluorescence 
spectra were determined with a Hitachi F-2500 spectrometer 
(Tokyo, Japan). The spectra of NLCs with Nile red were 
recorded with both slit widths set to 10 nm. The λex was 
fixed at 546 nm, and the emission spectra were recorded 
from 570 to 700 nm at a scanning speed of 300 nm/min.
Partition coefficient (log P) of drugs 
between the lipid and water phases
Partition coefficients were determined by equilibrating the 
drug partitioning between a melted lipid phase and a water 
phase. Three milligrams of calcipotriol (or methotrexate) was 
dispersed in a mixture of squalene (or melted Precirol) (1 g) 
and 1 ml of water and shaken for 10 min in a water bath at 
85°C. The aqueous phase was separated by centrifugation at 
5500 rpm for 10 min. The aqueous phase was subsequently 
filtered through a PVDF membrane with a pore size of 
0.45 µm. The drug concentration in the water phase was 
determined by HPLC.
High-performance liquid chromatographic 
(HPLC) analysis of the drugs
The HPLC system included a Hitachi L-2130 pump, 
a Hitachi L-2200 sample processor, and a Hitachi L-2400 
UV detector. A 25-cm-long, 4-mm inner diameter stainless 
steel C18 column (Merck, Darmstadt, Germany) was used. 
The mobile phases consisted of methanol: water (80:20) 
for calcipotriol and acetonitrile:water (15:85) at pH 2.7 
adjusted with phosphoric acid for methotrexate. The flow 
rate was 1 ml/min. The UV detector was set to wavelengths 
of 265 and 303 nm for calcipotriol and methotrexate, 
respectively.
In vitro skin permeation
The skin permeation of the antipsoriatic drugs was measured 
using a Franz cell assembly. Full-thickness dorsal skin of 
female nude mice (8 weeks old) was mounted between the 
donor and acceptor compartments. A cellulose membrane 
(Cellu-Sep® T2, with a molecular weight cutoff of 6000 
to 8000) was also used as a barrier in the experiments for 
examining drug release from the formulations. The donor 
medium consisted of 0.5 mL of vehicle containing drugs. International Journal of Nanomedicine 2010:5 120
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The actual amount of calcipotriol and methotrexate in donor 
was 300 µg and 400 µg, respectively. The receptor medium 
(5.5 mL) was ethanol: pH 7.4 buffer (3:7) to maintain sink 
conditions. The available diffusion area between cells was 
0.785 cm2. The stirring rate and temperature of receptor were 
respectively kept at 600 rpm and 37°C. The temperature of 
skin surface could be maintained at about 32°C after this 
setting, which was near the in vivo status. At appropriate 
intervals, 300-µL aliquots of the receptor medium were 
withdrawn and immediately replaced with equal volumes 
of fresh buffer. The cumulative amounts of both drugs were 
determined by HPLC.
Induction of hyperproliferative skin 
for in vitro skin permeation
Epidermal hyperproliferation simulating psoriasis-affected 
skin was achieved by a tape-stripping technique.14 Female 
nude mice (8 weeks old) were used in this study. All 
animal experiments were reviewed and approved by the 
Institutional Animal Care Committee at Chang Gung 
University (approval number: CGU07-09). Animals were 
housed and handled according to institutional guidelines. 
The dorsal skin of a mouse was stripped using cellophane 
tape (3M Scotch®) twice daily for 5 days. The stripping 
was repeated 10 times for each process. After 5 days, the 
skin was monitored by examining the transepidermal water 
loss (TEWL) with an evaporimeter (TM300, Courage and 
Khazaka, Köln, Germany). The skin was excised until the 
TEWL values reached 8 to 10 g/m2/h. The sample number 
of this experiment was four.
In vivo SRB and FITC delivery  
examined by Confocal Laser Scanning 
Microscopy (CLSM)
Localization of two dyes, SRB and FITC, within nude 
mouse skin was determined by CLSM after in vivo topical 
  application. A glass cylinder with an available area of 
0.785 cm2 was attached to the back skin of a nude mouse 
with glue. SRB and/or FITC in the vehicles at a concentration 
of 0.01 mM was added to each cylinder. The application 
duration was 2 hours. After excising the skin, it was wiped 
with a cotton cloth. The depth of penetration of SRB and 
FITC was directly examined by CLSM. The skin thickness 
was optically scanned at different increments through the 
z-axis of a Leica TCS SP2 confocal microscope (Wetzlar, 
Germany). Optical excitation was carried out with a 543-nm 
He-Ne laser, and λem was detected at 560 to 620 nm for SRB. 
The λex for FITC was 488 nm from an Ar laser, and the λem 
was detected at 496 to 559 nm.
In vivo skin irritation test
A 0.6-mL aliquot of NLCs without drugs was spread 
uniformly over a sheet of non-woven polyethylene cloth 
(1.5 × 1.5 cm), which was then applied to the back area of 
a nude mouse. The polyethylene cloth was fixed with Tega-
derm® adhesive dressing (3M, USA) and Fixomull® stretch 
adhesive tape (Beiersdorf AG, Germany). After 24 hours, the 
cloth was removed, and the treated skin area was swabbed 
clean with a cotton wool swab. After withdrawal of the vehi-
cle for 30 min, TEWL, colorimetric parameters, and the pH 
of the applied skin were measured. TEWL was recorded 
using a Tewameter® (TM300, Courage and Khazaka, 
Köln, Germany). The TEWL was automatically calculated 
and expressed in g/m2/h. A spectrocolorimeter (CD100, 
  Yokogawa Electrical, Tokyo, Japan) was used to measure the 
skin erythema (a*). The instrument recorded color reflectance 
three-dimensionally (L*, a*, and b*) as recommended by 
the Commission Internationale de l’Eclairage (CIE). The 
skin surface pH was determined by Skin-pH-Meter® PH 
905 (Courage and Khazaka). An adjacent untreated site 
was used as a baseline standard for each determination. The 
temperature and relative humidity in the laboratory were kept 
at 26°C and 55%, respectively. The sample number for each 
experiment was six (n = 6).
Statistical analysis
Statistical analysis of differences between different treat-
ments was performed using unpaired Student’s t-test. 
A 0.05 level of probability was taken as the level of sig-
nificance.
Results
Physicochemical characterization
NLCs made of Precirol and squalene as core materials 
were stabilized with Myverol and PF68. NLC dispersions 
composed of a 10% lipid phase were prepared using differ-
ent ratios of Precirol and squalene, ie, 3:7 (NLC-3P), 5:5 
(NLC-5P), and 7:3 (NLC-7P). First, the partition coefficients 
between the lipid and water was determined experimentally. 
As shown in Table 1, a greater amount of calcipotriol was 
incorporated in the lipid phase compared to methotrexate. 
Calcipotriol can partition into Precirol easier than into 
squalene (P  0.05). The same trend was observed for 
methotrexate although the discrepancy between the two 
lipids was limited.International Journal of Nanomedicine 2010:5 121
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Average diameters, polydispersity indexes (PDI), 
and surface charges of the developed NLCs are listed in 
Table 2. The composition of the nanoparticle core signifi-
cantly affected the size (P  0.05). The results showed that 
when increasing the Precirol concentration from 3% to 7%, 
the mean particle size increased from 267 to 320 nm. PDI 
were generally below 0.3 for all formulations, with no signifi-
cant difference (P  0.05) among the systems with various 
lipid ratios. Zeta potentials of the NLCs were −42 to −45 mV. 
A negligible effect of the lipid core on the surface charge was 
observed. NLC-7P showed a slightly lower negative charge 
(P  0.05) compared to the other systems.
The absorption bands of Nile red vary in shape, position, 
and intensity with the nature of the environment. The emission 
maximum of Nile red in organic solvents is near 600 nm. The 
emission spectra of Nile red in the nanoparticulate systems 
are shown in Figure 2. When incorporated into the NLCs, the 
increased re-orientation probability of the surrounding water 
molecules led to emission shifts to longer wavelengths. The 
fluorescence is quenched in a more-hydrophilic environment. 
The results indicated an increasing trend of hydrophilicity of   
NLC-3P  NLC-5P ≈ NLC-7P. The fluorescence intensities 
at 600 nm of NLC-5P and NLC-7P were comparable.
In vitro skin permeation
A key issue investigated in this study was the feasibility of 
using NLCs for the delivery of a double drug combination. 
The permeation abilities of calcipotriol and methotrexate 
were evaluated in vitro using Franz diffusion cells. Figure 3A 
shows the representative permeation kinetics of calcipotriol 
from NLCs in the absence of methotrexate. The control 
vehicle was 30% ethanol in water. The cumulative amounts 
of calcipotriol at different times in the receptor are shown, 
and the fluxes (µg/cm2/h) are summarized in Figure. 4A. For 
the control group, the flux of calcipotriol was 0.72 µg/cm2/h. 
NLC-5P (1.08 µg/cm2/h) and NLC-7P (1.01 µg/cm2/h) clearly 
promoted calcipotriol penetration compared to the control 
(P  0.05). NLC-3P (0.62 µg/cm2/h) showed a comparable 
flux (P  0.05) to the 30% ethanol vehicle. Figure 4A 
also compares calcipotriol permeation of a single drug 
with those permeated from NLCs loaded with dual drugs. 
All calcipotriol fluxes were reduced after incorporation of 
methotrexate in the systems, with the control and NLC-5P 
showing significant reductions (P  0.05).
When a drug is applied to the skin, two consecutive 
physical events may become rate-limiting steps in 
  cutaneous permeation: the release of the drug from the 
vehicle and its penetration through the skin barrier. Hence 
the ability of NLCs to deliver calcipotriol was examined 
by determining the release rate of the drug across cellulose 
membranes as depicted in Figure 4B. There was no 
  significant difference (P  0.05) among the release rates 
from the control, NLC-5P, and NLC-7P. NLC-3P exhibited 
a higher rate (P  0.05) than the other vehicles tested. 
Similar to the flux profiles, the addition of methotrexate in 
the formulations decreased calcipotriol release.
The cumulative amount-time profiles of methotrexate 
  permeation are given in Figure. 3B. Figure 5A shows the 
calculated methotrexate flux from 30% ethanol and NLCs. 
The control vehicle provided a flux of 0.25 µg/cm2/h for 
methotrexate delivery. Compared to the control, enhanced 
permeation was achieved with the NLCs. Methotrexate 
loading in the NLCs significantly increased the transport 
by 4.4-, 2.4-, and 3.0-fold, to 1.11, 0.61, and 0.75 µg/cm2/h, 
respectively, for NLC-3P, NLC-5P, and NLC-7P. There 
were no significant differences (P  0.05) in the release rates 
of methotrexate from all tested formulations (Figure 5B). 
  Neither the flux nor release rate changed after adding 
  calcipotriol to methotrexate-loaded vehicles (P  0.05).
In vitro skin permeation via 
hyperproliferative skin
Calcipotriol and methotrexate are extensively used for treating 
hyperproliferative skin diseases. Table 3 compares the fluxes 
across normal and hyperproliferative skin. NLC-5P with dual 
drugs was used as the representative model NLC preparation 
in this experiment. The 30% ethanol medium and NLC-5P 
showed no significant differences (P  0.05) in calcipotriol 
Table 1 The partition coefficient (log P) between lipids and water 
of calcipotriol and methotrexate
Lipid Calcipotriol Methotrexate
Precirol 3.86 ± 0.11 −0.70 ± 0.07
Squalene 2.05 ± 0.05 −0.91 ± 0.02
Note: Each value represents the mean ± SD (n = 5).
Table 2 The characterization of the nanostructured lipid carriers 
(NLCs) by particle size, polydispersity index (PDI), and zeta 
potential
Formulation Size (nm) PDI Zeta potential (mV)
NLC-3Pa 267.3 ± 12.3 0.25 ± 0.04 –44.6 ± 1.4
NLC-5Pb 304.5 ± 19.0 0.31 ± 0.13 –45.2 ± 1.1
NLC-7Pc 319.5 ± 12.2 0.29 ± 0.08 –41.8 ± 0.9
aNLC-3P, the inner phase composed of Precirol:squalene = 3:7.
bNLC-5P, the inner phase composed of Precirol:squalene = 5:5.
cNLC-7P, the inner phase composed of Precirol:squalene = 7:3.
Note: Each value represents the mean ± SD (n = 3).International Journal of Nanomedicine 2010:5 122
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permeation between the two skin types. Hyperproliferative 
skin exhibited higher methotrexate permeation (P  0.05) 
compared to normal skin; in particular, NLC-5P showed the 
greatest difference.
In vivo SRB and FITC delivery examined 
by CLSM
More in vivo studies should be conducted to support 
the in vitro findings. In order to explore the correlative 
  information about the skin targeting of NLCs, distribu-
tions of SRB and FITC in the skin were investigated using 
CLSM. The hydrophilic FITC likely resided in the external 
phase. SRB is more lipophilic than FITC.15 It is believed 
that SRB may appear in the inner phase of NLCs. Figure 6 
  illustrates the results obtained from CLSM following topical 
delivery of SRB loaded in 30% ethanol (Figure 6A) and 
NLC-5P (Figure 6B) without FITC incorporation. The skin 
  thickness was optically scanned at ∼10-µm increments for 
12 fragments from the surface of the skin (left to right, top 
to bottom). No or a negligible fluorescence response from 
the skin was observed for the 30% ethanol vehicle. It can 
be seen that the intensity of red fluorescence was much 
greater from NLCs than from the control. The fluorescence 
in the horizontal section at 30 to 75 µm was very strong 
and showed that SRB was rich in the epidermis and upper 
  dermis. Then the intensity gradually decreased with 
  increasing depth. The addition of FITC to the formulations 
did not significantly alter the fluorescence signal of SRB 
(Figures 6C, D). This result somewhat differs from that of 
the in vitro experiment.
The horizontal sectioning revealed green fluorescence for 
FITC as shown in Figure 7. There was almost no signal in 
skin treated with the FITC-loaded 30% vehicle (Figure 7A). 
Figure 7B depicts an increase in the fluorescence intensity 
with application of FITC-loaded NLCs. The amounts of FITC 
in viable epidermis and the superficial dermis were higher 
following the application of NLCs. The green signal of the 
systems with dual drugs was similar to that with FITC alone 
(Figures 7C, D).
In vivo skin irritation test
To ensure that the topical preparations are innocuous, it is 
necessary to study irritation caused by NLCs by determin-
ing their toxicity. TEWL, pH, and erythema (a*) were used 
to evaluate the preliminary safety of NLC-5P in vivo. The 
∆ value (the value of the treated site minus the value of an 
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Table 3 Comparison of calcipotriol and methotrexate flux (µg/cm2/h) between normal and hyperproliferative skins from the delivery 
carriers with dual drugs
Formulation Calcipotriol Methotrexate
Normal skin Hyperproliferative skin Normal skin Hyperproliferative skin
30% Ethanol 0.52 ± 0.03 0.50 ± 0.09 0.28 ± 0.07 0.42 ± 0.10*
NLC-5Pa 0.66 ± 0.17 0.55 ± 0.06 0.64 ± 0.02 1.14 ± 0.18*
aNLC-5P, the inner phase composed of Precirol:squalene = 5:5.
*P  0.05 as compared to the value of normal skin.
Note: Each value represents the mean ± SD (n = 4). International Journal of Nanomedicine 2010:5 123
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adjacent untreated site) was determined after a 24-hour 
administration as shown in Figure 8. No significant skin 
irritation was noted when the bar of the standard deviation 
(SD) passes across the zero line in Figure 8. Although these 
values increased after application of the NLCs, no significant 
irritation was detected. This suggests tolerable changes in the 
skin with the topical application of NLCs.
Discussion
Larger particles were seen in NLCs with low squalene 
loads. It is expected that the crystal order in the inner 
core is greatly disrupted by incorporating a liquid lipid 
although the carrier remains solid.16 The addition of a liquid 
lipid tends to promote the formulation of a small particle 
population as result of the higher molecular mobility of 
the matrix.17,18 PF68 is a non-ionic species. The negative 
surface charge shown by NLCs is believed to have resulted 
in the ionization of Myverol. Some free fatty acids derived 
from the hydrolysis of monoglycerides in Myverol may 
have occurred, contributing to the negative charge at the 
interface. The zeta potentials of NLC-3P and NLC-5P indi-
cated that additional negative charges existed compared to 
NLC-7P. This means that more Myverol may be exposed 
at the surface. Myverol is a lipophilic emulsifier. According 
to the results of examining the molecular environment, the 
lipophilicity of the particles decreased with an increase in 
the amount of squalene. Myverol molecules tend to escape 
the inner core with its low lipophilicity, thus exposing 
themselves in the shell of the particles. All produced NLCs 
possessed high zeta potentials for electrostatic repulsion, 
suggesting good physical stability.19,20
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The molecular environment was elucidated be examining 
the fluorescence intensity due to the solvatochromism of Nile 
red, a lipophilic benzophenoxazone dye. The fluorescence is 
quenched in aqueous media.21 Increasing Precirol in the NLCs 
generally created a more-lipophilic compartment for Nile red. 
The pronounced lipophilic character of Precirol expressed by 
a low HLB of 2 may have contributed to this result. Since Nile 
red shows only a weak intensity in a polar environment, the 
increase in the intensity with increasing Precirol indicates that 
the dye was transferred from the aqueous media or the inter-
face to the less-polar inner core.22 That is, Nile red in NLCs 
was preferentially found in the crystalline lipid phase. Hence 
it can be inferred that the lipophilic calcipotriol was largely 
embedded in the inner phase of the NLCs with the higher 
Precirol ratio. This inference can be confirmed by the greater 
partitioning of calcipotriol to Precirol than to squalene.
The drug permeating across the skin in the in vitro status 
dictates the amount available for skin absorption for some 
antipsoriatic drugs such as psoralens and methotrexate.23,24 
Hence, drug flux may be an indicator of the drug absorption 
to the targeted skin tissue. The kinetics of drug permeation 
are helpful to elucidate the mechanisms of drug aborption via 
the skin. Release of drug from the vehicle must occur before 
the drug can permeate into the skin. It was found that more 
calcipotriol was released from the system with less Precirol 
(NLC-3P) compared to the others. The encapsulated drug in 
particles diffuses to the surface of the inner phase and under-
goes partitioning between the lipid and aqueous phases.25 The 
drug amount in the outer shell and on the particle surface is 
released in the form of a burst.26 According to the results of 
the environmental polarity of the NLCs, calcipotriol may 
have largely been embedded in the interface of NLC-3P. 
The log P profiles also showed that calcipotriol much more   
easily was partitioned from squalene to the aqueous phase 
than that partitioned from Precirol. The expelled calcipotriol 
is poorly soluble in water, and hence the thermodynamic 
activity of calcipotriol increases. The progression of ther-
modynamic activity can explain the high drug diffusion of 
NLC-3P.27 The Precirol/squalene ratio can alter the structure 
of the particles, hence influencing drug release. The addition 
of a liquid lipid into the solid lipid matrix caused the crystal 
order of the NLCs to become more imperfect, and the loaded 
drug was more easily released.28,29 Another factor contribut-
ing to the rapid release of NLC-3P was its smaller particle 
size. The small size should create a larger total surface area, 
and an increased release rate would be expected.27
It can be seen that the release rate of calcipotriol is close 
to the flux value for all carriers examined. This indicates 
that calcipotriol easily penetrated into the stratum corneum 
(SC) from the vehicle. The relationship between the release 
rate and flux of the four vehicles tested was low (partition 
coefficient r2 = 0.263). This suggests that partitioning into 
the skin and subsequent penetration are predominant steps in 
topical calcipotriol delivery. Contrary to the results of release, 
NLC-5P and NLC-7P provided higher drug permeation rates 
than did NLC-3P. NLCs with a higher Precirol/squalene ratio 
even had enhanced calcipotriol flux compared to the control. 
The mechanisms through which this occurred are not clear, 
and different hypotheses have been put forth. These include 
enhancement of solubility, the large surface area due to the 
nanoparticulate size, an occlusive effect, and a penetration 
enhancer effect.30,31
In general, intact particles are considered to be unable 
to permeate the SC.18,32 Lipid nanoparticles can deliver 
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substances by interactions of the lipids used to construct 
the particles, and skin surface lipids.22,32 Precirol showed 
a higher lipophilicity than squalene, and thus might have a 
greater affinity for the SC. Larger amounts of NLC particles 
with higher Precirol loadings were able to partition into 
the SC. Calcipotriol might be transported with the lipid. 
A partitioning of NLC-5P and NLC-7P into the SC would 
result in a high accumulation of the drug. An increase in the 
concentration gradient leads to increased diffusion pressure 
of the drug into the skin.31,33 CLSM results also indicated that 
much greater amounts of the lipophilic SRB penetrated into 
the skin from NLCs than from the 30% ethanol vehicle.
Increased adhesiveness to surfaces is a general property 
of ultra-fine materials. Lipid nanoparticles adhering to the 
skin form a film which subsequently leads to an occlusive 
effect.12,26 The amount of encapsulated drug reaching the site 
of action will increase. This effect should be meaningful for 
calcipotriol since the therapeutic response to calcipotriol 
can be increased by occlusion with a polyethylene film 
or hydrocolloid dressing.34,35 The use of NLCs should be 
a reliable basis for enhancing the capability of topical 
drug delivery due to their construction. A previous study 
proved that fatty acids can be skin penetration enhancers of 
  calcipotriol.6 The free fatty acids derived from Precirol and 
Myverol in the particles may play this role of promoting 
calcipotriol permeation. This might explain the higher flux 
from NLC systems with a higher Precirol concentration.
Most of the formulations showed reduced calcipotriol 
release/permeation after methotrexate incorporation, although 
the differences were not always statistically significant. The 
incorporation of dual drugs into NLCs did not significantly 
alter the particle size or zeta potential (P  0.05, data not 
shown). This may have been due to the extremely low dose 
of the drugs. The physicochemical properties of NLCs cannot 
explain this reduction. The possibility of complex formation 
between calcipotriol and methotrexate molecules was 
considered. The –OH groups in the cyclohexane moiety of 
calcipotriol may interact with –NH2 groups in methotrexate’s 
structure to form H-bonding. Moreover, the electronegative 
oxygen in the –COOH and –CONH groups of methotrexate 
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Figure 6 Confocal laser scanning microscopic (CLSM) micrographs of nude mouse skin after the in vivo topical administration of sulforhodamine B (SRB) via the skin for 
2 hours from 30% ethanol (control) without fluorescein isothiocyanate (FITC) loading (A) NLC-5P without FITC loading (B) 30% ethanol (control) with FITC loading 
(C) NLC-5P with FITC loading (D).
Notes: The skin specimen was viewed by CLSM at ∼10-µm increments through the Z-axis from skin surface. The arrows indicate the skin fragments from surface to 
bottom.International Journal of Nanomedicine 2010:5 126
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might interact with –OH groups of calcipotriol. Many nitrogen 
molecules in methotrexate’s structure can also donate lone 
pairs to attach to –OH of calcipotriol. This indicates that 
interactions between these two drugs might have played an 
important role in decreasing calcipotriol permeation. In the 
initial process of calcipotriol release, the drug undergoes a 
partitioning from the lipid phase to the aqueous phase. Then 
calcipotriol is released into the outer phase for subsequent 
partitioning into the SC. A large amount of methotrexate 
would interact with calcipotriol in the aqueous phase. This 
phenomenon may impede further calcipotriol permeation via 
skin or a cellulose membrane. The in vivo CLSM results did 
not show a reduction, since there was no interaction between 
SRB and FITC. However, this effect would negligibly influ-
ence methotrexate permeation, because only a small portion 
of methotrexate molecules in the aqueous phase would form 
a complex. Further study is needed to elucidate the detailed 
mechanisms of this possible interaction.
Methotrexate is hydrosoluble, and thus has higher affinity 
for the aqueous phase.36 Since this is the external phase in 
NLCs, a greater amount of methotrexate is solubilized there. 
Because the diffusion of methotrexate is favored when it is 
incorporated into aqueous vehicles, we observed the effective 
methotrexate release from NLCs across a cellulose mem-
brane. This also indicates that the lipid particles themselves 
did not significantly influence methotrexate release. The flux 
value of methotrexate was lower compared to the release rate 
of calcipotriol from all vehicles. This was due to a critical 
barrier function of the SC for the hydrophilic methotrex-
ate.24,36 Both in vitro and in vivo permeation results revealed 
the enhanced delivery of methotrexate by NLC systems, with 
NLC-3P showing the greatest ability. The lipid particles must 
have some effects on the skin to induce this enhancement.
Similar to the case of calcipotriol, lipid particles form 
an adhesive layer occluding the skin surface. The hydration 
of the SC increases by reducing keratinocyte packing, and 
widening of the intercellular bilayers can facilitate drug 
penetration into deeper strata. This effect might be more 
pronounced for methotrexate than calcipotriol since adhesion 
increases with decreasing particle size.31,37 The penetration 
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Figure 7 Confocal laser scanning microscopic (CLSM) micrographs of nude mouse skin after the in vivo topical administration of fluorescein isothiocyanate (FITC) via the 
skin for 2 h from 30% ethanol (control) without sulforhodamine B (SRB) loading (A) NLC-5P without SRB loading (B) 30% ethanol (control) with SRB loading (C) NLC-5P 
with SRB loading (D).
Notes: The skin specimen was viewed by CLSM at ∼10-µm increments through the Z-axis from skin surface. The arrows indicate the skin fragments from surface to 
  bottom.International Journal of Nanomedicine 2010:5 127
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of methotrexate from NLCs might not only be explained by 
an occlusive effect. Previous research35 suggested that the 
component emulsifiers in oil-in-water emulsions can reduce 
the functional barrier of the SC. Saturated and unsaturated 
fatty acids are frequently used as the lipid phase to enhance 
penetration.38 Precirol and Myverol in NLCs may act as 
  penetration enhancers for methotrexate delivery. Clinical 
results with local methotrexate have been disappointing.39 
A major problem is that the drug is hydrophilic, has a high 
molecular weight (455 Da), and is mostly in the dissociated 
form at a physiological pH.2 NLCs can enhance the topical 
delivery of this drug to resolve this issue. A detailed 
  investigation of the enhancing effect on drug permeation 
was not the main effort of this study. The basic mechanism 
should be elucidated in future studies.
Psoriasis is a disorder triggered when activated 
  immunocytes infiltrate the skin, subsequently inducing 
  prominent epidermal thickening. We used a tape-stripping 
technique to create hyperproliferative skin. It was confirmed 
that this method can induce psoriasis-like skin characterized 
by epidermal hyperplasia. It increased the epidermal thick-
ness by 1.5-fold.17 Calcipotriol flux showed no significant 
  difference in hyperproliferative skin compared to normal 
skin. Although a longer pathway through which the drug 
had to pass was created by the psoriasis-like skin, a greater 
increase in methotrexate permeation via this skin was 
observed, especially for the NLC formulations. This may 
have been due to disruption of the permeability barrier in the 
hyperproliferative skin.14 Hence the NLC system can exert 
greater potency in treating psoriasis in disordered skin.
TEWL is used to assess the degree of SC disruption.40 
The a*-coordinate of colorimetry (which indicates erythema) 
has been demonstrated to correlate well with inflammatory 
  interactions of the skin, especially in viable skin. NLCs 
showed no or only negligible increases in TEWL and a*. 
This suggests good tolerance of NLCs by the skin in this 
  preliminary safety test. According to the hypothesis of 
enhancing drug permeation by NLCs, the nanoparticles as 
penetration enhancers may produce SC perturbations. The 
TEWL results indicated limited SC disruption by NLCs. 
It has been shown that the complete removal of lipids from 
the SC leads to a 100-fold increase in water permeability.41
Conclusions
Psoriasis often reoccurs and is rarely cured, and hence patients 
should receive therapy periodically over many years. Thus, the 
development of vehicles for delivering multiple drugs to effi-
ciently treat psoriasis is urgently needed. NLCs incorporating 
calcipotriol and methotrexate were developed and evaluated 
to achieve this aim. The present work confirmed that NLC 
systems are a promising carrier for the topical delivery of 
antipsoriatic drugs as revealed by enhanced skin permeation, 
negligible skin irritation, and the compatibility of the two 
drugs. A good correlation between in vitro and in vivo results 
was obtained. The skin permeation of methotrexate can be 
potentiated by using hyperproliferative skin as the penetration 
barrier. This is important for NLC administration on psoriatic 
skin. Most research related to topically applied SLNs or NLCs 
has demonstrated enhanced permeation of the drugs in lipid 
cores. We have proven that the drug in the aqueous phase 
also exhibits enhanced delivery with NLCs.
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